By: Tampa Bay Radiation Oncology Radiation is often a treatment option for cancer. While the procedure itself is usually painless, that doesn’t mean that you won’t feel anxious or overwhelmed—or even scared. Those feelings are perfectly understandable, and you should know that you’re not alone in feeling this way. Knowing what to expect from radiation treatment will help you feel more prepared …
Cancer researchers find more effective way to deliver promising breast cancer treatment
By: Adrianna MacPherson, University of Alberta From: medicalxpress.com A cancer researcher at the University of Alberta and his team are breathing new life into a promising cancer therapy by improving how the treatment is delivered. Hasan Uludag, a professor in chemical and materials engineering, and his team have developed a chemical compound that allows them to effectively inject genetic material …
What You Need to Know About the FDA’s Approval of Tukysa for HER2-Positive Breast Cancer
By: Beth Fand Incollingo and Kristi Rosa From: curetoday.com By approving Tukysa (tucatinib) for use with the targeted drug Herceptin (trastuzumab) and the chemotherapy Xeloda (capecitabine), the Food and Drug Administration has provided a meaningful option to heavily pretreated patients with inoperable, locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, according to Dr. Rashmi Murthy. This …
Hormone Levels Tied to Future Breast Cancer Risk
By: Kristen Monaco From: medpagetoday.com Circulating progesterone levels may help predict future breast cancer incidence in older women, researchers reported. During a 12-year follow-up period, postmenopausal women saw a modest 16% higher risk for breast cancer with each standard deviation increase in progesterone levels (hazard 1.16, 95% CI 1.00-1.35, P=0.048), Britton Trabert, PhD, MS, of the National Cancer Institute in …
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial
Source: Generex Biotechnology Corporation From: globenewswire.com Prospective, randomized, single‑blinded, multi‑center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Conclusion: AE37 Ii-Key peptide vaccine is safe and associated with DFS in sub-sets of breast cancer survivors after 10-year follow-up In patients with both advanced stage and HER2 under-expression (HER2 2+, 1+, …
Poor Endocrine Therapy Response in Primary Breast Cancer Possibly Explained by Rare ESR1 Mutations
By: Andrea Anderson From: precisiononcologynews.com Mutations in the estrogen receptor alpha-coding gene ESR1 appear to occur in a small subset of primary breast cancer tumors, potentially providing a window into cases with poorer-than-usual responses to adjuvant, endocrine-based treatments. Several prior studies suggest activating mutations in ESR1 can contribute to treatment resistance in metastatic breast cancer cases, explained Malin Dahlgren, a …
New fast-track breast cancer treatment takes just FIVE DAYS instead of the standard three weeks
By: Ben Spencer From: dailymail.co.uk An NHS trial reveals a five-day course of radiotherapy is as good as three weeks The high-dosage is proven to be as safe as the standard breast cancer treatment Hospitals are using the fast-track regime as it reduces coronavirus exposure Here’s how to help people impacted by Covid-19 Nearly 35,000 breast cancer patients a year …
New type of immune cell discovered in breast ducts
Source: Walter and Eliza Hall Institute From: eurekalert.org Melbourne breast cancer researchers have discovered a new type of immune cell that helps to keep breast tissue healthy by regulating a vital process within mammary ducts – the sites where milk is produced and transported, but also where most breast cancers arise. Using advanced three-dimensional (3D) imaging techniques, the team observed …
Getting Your Cancer Screenings and Treatments at This Time
View PostDurvalumab regimen improves pathologic complete response in HER2-negative breast cancer
From: healio.com Durvalumab and olaparib in combination with paclitaxel significantly improved pathologic complete response compared with chemotherapy alone among women with stage II or stage III high-risk, HER2-negative breast cancer, according to results of the randomized phase 2 I-SPY 2 study presented at the virtual American Association for Cancer Research Annual Meeting. Researchers observed improvement among subsets of women with …